Sonoma Pharmaceuticals Inc. (SNOA) Financial Statements (2024 and earlier)

Company Profile

Business Address 5445 CONESTOGA COURT, SUITE 150
BOULDER, CO 80301
State of Incorp. DE
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2023
MRQ
3/31/2023
3/31/2022
3/31/2021
3/31/2020
3/31/2019
3/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,8207,3964,2203,6913,68910,066
Cash and cash equivalents3,8207,3964,2203,6913,68910,066
Receivables2,5722,4072,8064,0623,4811,537
Inventory, net of allowances, customer advances and progress billings2,8582,6632,5302,1923,4092,865
Inventory2,8582,6632,5302,1923,4092,865
Prepaid expense 4,3083,7463,2182,2561,6161,277
Other undisclosed current assets240218209182301509
Total current assets:13,79816,43012,98312,38312,49616,254
Noncurrent Assets
Operating lease, right-of-use asset418559769963
Property, plant and equipment4883203603657271,136
Deferred income tax assets949829  
Other noncurrent assets737711264122494
Other undisclosed noncurrent assets5056307637861,1031,322
Total noncurrent assets:2,4332,4152,0042,1781,9522,952
TOTAL ASSETS:16,23118,84514,98714,56114,44819,206
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,8704,5432,9233,8602,7562,678
Employee-related liabilities1,0597871,078957817
Accounts payable8411,6411,7692,0861,2551,272
Accrued liabilities 2,0291,843367696544589
Deferred revenue1001,223267228
Debt431808596481463377
Other liabilities     270 
Other undisclosed current liabilities316(755)292296102206
Total current liabilities:3,7175,8194,0784,8653,5913,261
Noncurrent Liabilities
Long-term debt and lease obligation  3091,83974612176
Long-term debt, excluding current maturities   1,310 1232
Capital lease obligations 144
Liabilities, other than long-term debt302182229245  
Deferred revenue140182229245
Operating lease, liability162309529746
Other undisclosed noncurrent liabilities4,2353,8383,478 356443
Total noncurrent liabilities:4,5374,3295,546991368619
Total liabilities:8,25410,1489,6245,8563,9593,880
Equity
Equity, attributable to parent7,9778,6975,3638,70510,48915,326
Common stock522221
Additional paid in capital200,904197,370189,217186,559184,074176,740
Accumulated other comprehensive loss(3,418)(4,312)(4,579)(5,610)(4,349)(3,975)
Accumulated deficit(189,514)(184,363)(179,277)(172,246)(169,238)(157,440)
Total equity:7,9778,6975,3638,70510,48915,326
TOTAL LIABILITIES AND EQUITY:16,23118,84514,98714,56114,44819,206

Income Statement (P&L) ($ in thousands)

12/31/2023
TTM
3/31/2023
3/31/2022
3/31/2021
3/31/2020
3/31/2019
3/31/2018
Revenues13,27212,62818,62918,93618,97016,658
Cost of revenue(8,795)(8,635)(12,070)(10,603)(10,090)(9,348)
Cost of goods and services sold(8,795)(8,635)(12,070)(10,603)(231)(198)
Gross profit:4,4773,9936,5598,3338,8807,310
Operating expenses(9,047)(9,880)(10,008)(15,004)(20,138)(21,499)
Operating loss:(4,570)(5,887)(3,449)(6,671)(11,258)(14,189)
Nonoperating income
(Investment Income, Nonoperating)
   1650190258
Interest and debt expense  723(12)(16)(33)(40)
Loss from continuing operations before equity method investments, income taxes:(4,570)(5,164)(3,445)(6,637)(11,101)(13,971)
Other undisclosed income (loss) from continuing operations before income taxes(614)(254)(457)3,812(239)(357)
Loss from continuing operations before income taxes:(5,184)(5,418)(3,902)(2,825)(11,340)(14,328)
Income tax expense (benefit)33332(713)(121)(458) 
Other undisclosed loss from continuing operations      
Loss from continuing operations:(5,151)(5,086)(4,615)(2,946)(11,798)(14,328)
Loss before gain (loss) on sale of properties:(5,086)(3,950)(2,946)(11,798)(14,328)
Income from discontinued operations   665   
Other undisclosed net loss(31)(313)    
Net loss:(5,182)(5,399)(3,950)(2,946)(11,798)(14,328)
Other undisclosed net income attributable to parent31313    
Net loss available to common stockholders, diluted:(5,151)(5,086)(3,950)(2,946)(11,798)(14,328)

Comprehensive Income ($ in thousands)

12/31/2023
TTM
3/31/2023
3/31/2022
3/31/2021
3/31/2020
3/31/2019
3/31/2018
Net loss:(5,182)(5,399)(3,950)(2,946)(11,798)(14,328)
Other comprehensive loss   (2,919)(4,207)(12,172)(14,125)
Other undisclosed comprehensive income925580    
Comprehensive loss, net of tax, attributable to parent:(4,257)(4,819)(6,869)(7,153)(23,970)(28,453)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: